Being a potent anticancer agent, fisetin administration in in vitro and in vivo studies in kidney renal stem cells (HuRCSCs) effectively inhibited cancer cell stages such as proliferation, cell division, and invasion as well as lowered the TET1 expression levels. The gene discussed is TET1; the disease is cancer.